Evercore ISI upgraded Augmedix (AUGX) to Outperform from In Line with a $5 price target. The firm sees Augmedix continuing with its strong momentum, further bolstered by its recent go-to-market partnership with SADA, and believes progression with HCA Healthcare (HCA) and related announcements will be a short-term catalyst.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUGX:
- Augmedix Integrates with Andor Health to Revolutionize Ambient Clinical Documentation for Ambulatory Virtual Care
- Augmedix and SADA Forge Partnership to Scale Ambient Documentation and Structured Data Products to Health Systems Nationwide
- Augmedix and SADA in partnership to scale ambient documentation, no terms
- Augmedix resumed with a Buy at B. Riley
- Augmedix price target lowered to $4.50 from $6.50 at Evercore ISI